Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis

Canadian Journal of Gastroenterology

Volumn 24, Issue 7, 2010, Pages 435-440

  He, Yi Fu ^a   Jin, Juan ^a   Wei, Wei ^a   Chang, Yan ^a   Hu, Bing ^a   Ji, Chu Shu ^a   Jia, Wei Dong ^a   Wang, Xiao Qiu ^a   Chen, Ke ^a   Chen, Jian ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cyclooxygenase 2; Hepatic resection; Hepatocellular carcinoma; Prognosis; Recurrence

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; GENE OVEREXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BLOOD VESSEL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

EID: 77954972496     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2010/872570     Document Type: Article

References (43)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
2. 90Yttrium microspheres. Int J Radiat Oncol Biol Phys 1998;40:583-92.
3. Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg 1998;85:1319-31.
4. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
5. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in noncancerous liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999;5:4005-12.
6. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: Relevance to tumor dedifferentiation. Hepatology 1999;29:688-96.
7. Morinaga S, Yamamoto Y, Noguchi Y, et al. Cyclooxygenase-2 mRNA is up-regulated in cirrhotic or chronic hepatitis liver adjacent to hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:1110-6.
8. Mohammed NA, Abd El-Aleem SA, El-Hafiz HA, McMahon RF. Distribution of constitutive (COX-1) and inducible (COX-2) cyclooxygenase in postviral human liver cirrhosis: A possible role for COX-2 in the pathogenesis of liver cirrhosis. J Clin Pathol 2004;57:350-4.
9. Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK. The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 2004;17:35-8.
10. Cheng J, Imanishi H, Iijima H, et al. Expression of cyclooxygenase-2 and cytosolic phospholipase A2 in the liver tissue of patients with chronic hepatitis and liver cirrhosis. Hepatol Res 2002;23:185-95.
11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17.
12. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1):S35-50.
13. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:47-53.
14. Gentilini P, Melani L, Riccardi D, Casini Raggi V, Romanelli RG. Hepatocellular carcinoma and viral cirrhosis. Hepatology 1994;20:764-5.
15. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. Clin Virol 2005;34(Suppl 1):S75-78.
16. Marotta F, Vangieri B, Cecere A, Gattoni A. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect. Clin Ter 2004;155:187-99.
17. Oliveri F, Brunetto MR, Actis GC, Bonino F. Pathobiology of chronic hepatitis virus infection and hepatocellular carcinoma (HCC). Ital J Gastroenterol 1991;23:498-502.
18. Al-Haddad S, Zhang Z, Leygue E, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999;155:2057-66
19. Handra-Luca A, Bilal H, Bertrand JC, et al. Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: Association to aggressive tumor behavior and tumor cell proliferation. Am J Pathol 2003;163:957-67
20. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91.
21. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
22. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
23. Assy N, Minuk GY. Serum aspartate but not alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenterol 2000;95:1545-50.
24. Couinaud C. Anatomic principles of left and right regulated hepatectomy. Technics J Chir 1954;70:933-66.
25. Wu CC, Chen JT, Ho WL, et al. Liver resection for hepatocellular carcinoma in octogenarians. Surgery 1999;125:332-8.
26. Qiang L, Huikai L, Butt K, Wang PP, Hao X. Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma. World J Surg 2006;30:439-45.
27. Bilimoria MM, Lauwers GY, Doherty DA, et al. Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001;136:528-35.
28. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-22.
29. Takenaka K, Adachi E, Nishizaki T, et al. Possible multicentric occurrence of hepatocellular carcinoma: A clinicopathological study. Hepatology 1994;19:889-94.
30. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92.
31. Tang TC, Poon RT, Lau CP, Xie D, Fan ST. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 2005;11:1896-902.
32. Cheng AS, Chan HL, Leung NW, et al. Expression of cyclooxygenase-2 in chronic hepatitis B and the effects of anti-viral therapy. Aliment Pharmacol Ther 2002;16:251-60.
33. Bryn T, Yaqub S, Mahic M, et al. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol 2008;20:235-45.
34. You J, Sriplung H, Geater A, et al. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol 2008;14:1112-9.
35. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 998;280:1036-7.
36. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: A new class of anticancer agents? Lancet Oncol 2003;4:605-15.
37. Moon EJ, Jeong CH, Jeong JW, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1 alpha. FASEB J 2004;18:382-4.
38. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002;110:1831-8.
39. Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: Implication of HBx in upregulation of COX-2. Mod Pathol 2004;17:1169-79.
40. Kim BK, Park JY, Kim do Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008;28:393-401.
41. Hung IF, Poon RT, Lai CL, et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol 2008;103:1663-73.
42. Huang Y, Wang Z, An S, et al. Role of hepatitis B virus genotypes and quantitative HBV DNA in metastasis and recurrence of hepatocellular carcinoma. J Med Virol 2008;80:591-7.
43. Kubo S, Tanaka H, Takemura S, et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res 2007;37:94-100.